BIOLASE, Inc. Provides Revenue Guidance for the Third Quarter of 2022 and Full Year of 2022
August 12, 2022 at 02:00 am IST
Share
BIOLASE, Inc. provided revenue guidance for the third quarter of 2022 and full year of 2022. For the third quarter period, the company expects revenue to be $10.5 million, which would represent growth of over 10% year-over-year.
For the full year, The company expects net revenue to increase at least 15% from 2021 levels.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.